Via BioCentury's Steve Usdin, this update:
Despite a setback from the Senate Armed Services Committee, which declined to add the Biosecure Act to the bipartisan consensus draft of a must-pass defense bill, the legislation could still reach President Joe Biden’s desk this year.
Shares of contract development, research and manufacturing companies that would be directly affected by proposed restrictions on U.S. government contracting with Chinese biotech companies jumped Friday on the news that the Biosecure Act wasn’t included in a package of 93 amendments to the FY25 National Defense Authorization Act (NDAA).
I can't read the whole article (nor is this move corroborated anywhere), but Usdin is well known, so this is likely true. I expected this bill to slow once it hit the Senate, so this tracks.
No comments:
Post a Comment
looks like Blogger doesn't work with anonymous comments from Chrome browsers at the moment - works in Microsoft Edge, or from Chrome with a Blogger account - sorry! CJ 3/21/20